

Cover Story
Free
Congressional Panel Chair Questions Whether J&J, Brigham Reported Morcellation Adverse Events to FDA
By Matthew Bin Han Ong
The House Committee on Energy & Commerce has stepped into a key role in the controversy over power morcellation.
In Brief


Drugs & Targets
Trending Stories
- Class action complaint alleging GRAIL insider fraud resubmitted after dismissal
- Cancer centers adapt to life without site visits as NIH changes CCSG review
- How GLP-1RA drugs are reshaping patient physiology and the future of oncology
- Friends publishes three white papers ahead of annual meeting
Topics: Clinical trials on rare cancers, combination drug trials, multi-regional studies - Jonathan Licht named president, chief scientific officer at Van Andel Institute
- Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA











